AC
REGN icon

AlphaCore Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

AlphaCore Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$428K Sell
686
-170
-20% -$116K 0.01% 763
2026
Q1 		$661K Buy
856
+377
+79% +$289K 0.02% 478
2025
Q4 		$370K Buy
+479
New +$325K 0.01% 714

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

AlphaCore Capital's REGN Position: Q2 2026 in Review

AlphaCore Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 20% in Q2 2026, selling an estimated $116K and leaving 686 shares worth $428K. The position accounts for 0.01% of the portfolio, ranked #763.

AlphaCore Capital first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $661K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • AlphaCore Capital held 686 shares of Regeneron Pharmaceuticals worth $428K as of Q2 2026.
  • AlphaCore Capital sold 170 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $116K.
  • Regeneron Pharmaceuticals made up 0.01% of AlphaCore Capital's portfolio in Q2 2026, its #763 holding.
  • AlphaCore Capital first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • AlphaCore Capital's Regeneron Pharmaceuticals position peaked at $661K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.